Source:http://linkedlifedata.com/resource/pubmed/id/10534322
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1999-11-24
|
pubmed:abstractText |
Tirofiban hydrochloride [L-tyrosine-N-(butylsulfonyl)-O-[4-(4-piperidinebutyl)] monohydrochloride, is a potent and specific fibrinogen receptor antagonist. Radiolabeled tirofiban was synthesized with either (3)H-label incorporated into the phenyl ring of the tyrosinyl residue or (14)C-label in the butane sulfonyl moiety. Neither human liver microsomes nor liver slices metabolized [(14)C]tirofiban. However, male rat liver microsomes converted a limited amount of the substrate to a more polar metabolite (I) and a relatively less polar metabolite (II). The formation of I was sex dependent and resulted from an O-dealkylation reaction catalyzed by CYP3A2. Metabolite II was identified as a 2-piperidone analog of tirofiban. There was no evidence for Phase II biotransformation of tirofiban by microsomes fortified with uridine-5'-diphospho-alpha-D-glucuronic acid. After a 1 mg/kg i.v. dose of [(14)C]tirofiban, recoveries of radioactivity in rat urine and bile were 23 and 73%, respectively. Metabolite I and unchanged tirofiban represented 70 and 30% of the urinary radioactivity, respectively. Tirofiban represented >90% of the biliary radioactivity. At least three minor biliary metabolites represented the remainder of the radioactivity. One of them was identified as I. Another was identified as II. When dogs received 1 mg/kg i.v. of [(3)H]tirofiban, most of the radioactivity was recovered in the feces as unchanged tirofiban. The plasma half-life of tirofiban was short in both rats and dogs, and tirofiban was not concentrated in tissues other than those of the vasculature and excretory organs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0090-9556
|
pubmed:author |
pubmed-author:ArisonBB,
pubmed-author:BalaniS KSK,
pubmed-author:CuiDD,
pubmed-author:DuncanC ACA,
pubmed-author:EllisJ DJD,
pubmed-author:GorhamL MLM,
pubmed-author:PolskyS LSL,
pubmed-author:PrueksaritanontTT,
pubmed-author:RamageP IPI,
pubmed-author:SlaughterD EDE,
pubmed-author:TheoharidesA DAD,
pubmed-author:VickersSS,
pubmed-author:VyasK PKP
|
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1360-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10534322-Animals,
pubmed-meshheading:10534322-Bile,
pubmed-meshheading:10534322-Dogs,
pubmed-meshheading:10534322-Feces,
pubmed-meshheading:10534322-Female,
pubmed-meshheading:10534322-Fibrinolytic Agents,
pubmed-meshheading:10534322-Half-Life,
pubmed-meshheading:10534322-Humans,
pubmed-meshheading:10534322-Male,
pubmed-meshheading:10534322-Protein Binding,
pubmed-meshheading:10534322-Rats,
pubmed-meshheading:10534322-Rats, Sprague-Dawley,
pubmed-meshheading:10534322-Tissue Distribution,
pubmed-meshheading:10534322-Tyrosine
|
pubmed:year |
1999
|
pubmed:articleTitle |
In vitro and in vivo studies on the metabolism of tirofiban.
|
pubmed:affiliation |
Merck Research Laboratories, West Point, Pennsylvania 19486-0004, USA. stanley_vickers@merck.com
|
pubmed:publicationType |
Journal Article
|